Relationship between primary patency and lesion length following bare nitinol stent placement for femoropopliteal disease

Journal of Endovascular Therapy

Volumn 22, Issue 6, 2015, Pages 862-867

  Soga, Yoshimitsu ^a   Takahara, Mitsuyoshi ^b   Iida, Osamu ^c   Suzuki, Kenji ^d   Hirano, Keisuke ^e   Kawasaki, Daizo ^f   Shintani, Yoshiaki ^g   Yamaoka, Terutoshi ^h   Ando, Kenji ^a  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

^d SAISEIKAI CENTRAL HOSPITAL   (Japan)

^e SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^f HYOGO COLLEGE OF MEDICINE   (Japan)

^g Shin Koga Hospital   (Japan)

^h MATSUYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

Endovascular therapy; Femoropopliteal disease; Lesion length; Occlusion; Patency; Popliteal artery; Stenosis; Stent; Superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; TICLOPIDINE; ALLOY; NITINOL;

AGED; ARTICLE; BARE METAL STENT; BARE NITINOL STENT; CONFIDENCE INTERVAL; FEMALE; FEMOROPOPLITEAL DISEASE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; NITINOL STENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SELF EXPANDING NITINOL STENT; STENT FRACTURE; ATHEROSCLEROSIS; ENDOVASCULAR SURGERY; FEMORAL ARTERY; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS DESIGN; STENT; VASCULAR PATENCY;

AGED; ALLOYS; ATHEROSCLEROSIS; ENDOVASCULAR PROCEDURES; FEMALE; FEMORAL ARTERY; HUMANS; MALE; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; STENTS; VASCULAR PATENCY;

EID: 84947902647     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602815610118     Document Type: Article

References (16)

1. Pokrajac B, Pötter R, Wolfram RM, et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna-3 randomised multicenter study. Radiother Oncol. 2005; 74: 3-9.
2. Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol. 1999; 18: 251-255.
3. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation. 2000; 102: 2694-2699.
4. van der Zaag ES, Legemate DA, Prins MH, et al. Angioplasty or bypass for superficial femoral artery disease? A randomised controlled trial. Eur J Vasc Endovasc Surg. 2004; 28: 132-137.
5. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006; 354: 1879-1888.
6. Mewissen MW Primary nitinol stenting for femoropopliteal disease. J Endovasc Ther. 2009; 16(2 suppl 2):II63-II81.
7. Soga Y, Iida O, Hirano K, et al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010; 52: 608-615.
8. Vardi M, Novack V, Pencina MJ, et al. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv. 2014; 83: 975-983.
9. Rocha-Singh KJ, Jaff MR, Crabtree TR, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007; 69: 910-919.
10. Miki K, Fujii K, Fukunaga M, et al. Impact of post-procedural intravascular ultrasound findings on long-term results following self-expanding nitinol stenting in superficial femoral artery lesions. Circ J. 2013; 77: 1543-1550.
11. Zeller T, Peeters P, Bosiers M, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial. J Endovasc Ther. 2014; 21: 765-774.
12. Werner M, Paetzold A, Banning-Eichenseer U, et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014; 10: 861-868.
13. Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013; 6: 1295-1302.
14. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and singlearm clinical studies. J Am Coll Cardiol. 2013; 61: 2417-2427.
15. Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011; 78: 611-617.
16. Bosiers M, Deloose K, Callaert J, et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011; 54: 1042-1050.